Here are the 424B prospectus supplements from Nanobiotix Labege (NNBXF) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow NNBXF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NNBXF filings page.
Nanobiotix S.A. is conducting a global offering of 2,184,662 ordinary shares and 345,099 pre-funded warrants, consisting of a U.S. offering of 225,373 ADSs (one ADS = one ordinary share) and a European offering of 1,959,289 ordinary shares plus 345,099 pre-funded warrants.
The public offering price is €33.60 per ordinary share (ADS price $38.98), and each pre-funded warrant is priced at €33.57 with an exercise price of €0.03 per ordinary share. Net proceeds are estimated at approximately €79.12 million (before expenses), and the underwriters have a 30‑day option to purchase up to 33,805 additional ordinary shares, which would increase estimated net proceeds to €80.89 million.
Shares outstanding were 48,410,068 ordinary shares as of December 31, 2025. The pre-funded warrants are not expected to trade on any exchange and contain beneficiary ownership caps that limit exercises above specified thresholds.